REGENTIS BIOMATERIALS LTD. IPO Filing Research

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Price $3.00 · 3,333,334 shares

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 500,000 · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an IPO to raise capital through the offering of 3,333,334 ordinary shares at an assumed public price of $3.00. The company, an emerging growth company and foreign private issuer, focuses on orthopedic treatments using its Gelrin platform for cartilage repair. GelrinC, its lead product, is CE-marked in Europe but not yet approved in the U.S. The company is advancing a pivotal trial for FDA approval and has recently appointed new leadership, including a new CEO and CFO, while collaborating with Humanitas Hospital in Italy.

2026-05-01 · 0001213900-26-051034

20-F supplemental

20-F

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B3 in the pre-IPO sequence.

The current 20-F filing for Regentis Biomaterials Ltd. includes detailed financial disclosures and XBRL-tagged data, transitioning from a previous DRS. The text focuses on financial metrics, stock compensation, and IPO-related terms, but lacks a comprehensive narrative. The filing appears to be a formal annual report with technical financial data, though no explicit updates or changes from the prior DRS are clearly stated.

2026-02-24 · 0001213900-26-019917

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Regentis Biomaterials Ltd. is conducting a firm commitment offering of ordinary shares, with its lead product GelrinC targeting unmet needs in knee cartilage repair. The company, an emerging growth company and foreign private issuer, emphasizes its technology's potential for long-term outcomes compared to existing treatments like microfracture surgery. The offering is subject to regulatory approvals and market risks.

2026-01-07 · 0001213900-26-002202

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows CERT and confirms the priced prospectus.

Price $8.00 · 1,250,000 shares · Gross proceeds $10,000,000

Ordinary Shares, no par value · Exchange NYSE American · Ticker RGNT · Over-allotment 187,500 · Use of proceeds for working capital and general corporate purposes · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, totaling $10 million. The shares will be listed on the NYSE American under the symbol RGNT. The company, an emerging growth company and foreign private issuer, focuses on orthopedic treatments using its Gelrin platform, a hydrogel technology for cartilage regeneration. The lead product, GelrinC, received CE marking in 2017 and is in a pivotal trial for FDA approval. The offering includes underwriting discounts and a 45-day option for over-allotments.

2025-12-04 · 0001213900-25-118362

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

Follows FWP in the pre-IPO sequence.

Regentis Biomaterials Ltd. is seeking to raise approximately $4.5 million through the issuance of 1,000,000 ordinary shares at an expected price range of $10.00-$12.00 per share. The offering aims to fund clinical development, PMA submission, operations, R&D, EU marketing, loan repayments, deferred compensation, litigation settlements, and general corporate purposes. The company's GelrinC® hydrogel platform targets knee cartilage repair, with ongoing FDA pivotal trials and CE Mark approval in Europe. The offering highlights market potential in the $472,500+ annual U.S. knee cartilage repair procedures, positioning GelrinC as an off-the-shelf alternative to microfracture surgery.

2025-12-03 · 0001143313-25-000093

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows F-1/A and supplements the active offering with updated prospectus details.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds Proceeds will be used for clinical development, operations, R&D, EU marketing, loan repayment, deferred compensation, litigation, and general corporate purposes. · Underwriters ThinkEquity LLC

Regentis Biomaterials Ltd. is conducting a public offering of 1,000,000 ordinary shares at an expected price range of $10.00 to $12.00 per share. The offering aims to raise approximately $10 million for clinical development, PMA submission, operations, R&D, EU marketing, loan repayment, and working capital. The company focuses on GelrinC, an acellular hydrogel for knee cartilage repair, with CE Mark approval in Europe and an ongoing FDA pivotal trial. Key milestones include completing pivotal trial enrollment by Q4 2025 and PMA submission by Q4 2027.

2025-10-24 · 0001213900-25-101902

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds General corporate purposes · Flags foreign_private_issuer, emerging_growth_company · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an IPO of 1,000,000 ordinary shares at an expected price range of $10.00-$12.00 per share. The company focuses on regenerative medicine, with its lead product GelrinC for knee cartilage repair. GelrinC has CE mark approval in Europe and is in FDA pivotal trials. The offering includes a 45-day over-allotment option, with proceeds allocated to clinical development, operations, R&D, EU marketing, debt repayment, and general corporate purposes. The company is an emerging growth company and foreign private issuer.

2025-10-24 · 0001213900-25-101900

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows F-1/A and supplements the active offering with updated prospectus details.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares of Regentis Biomaterials Ltd. · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds Proceeds will be used for clinical development, operations, R&D, EU marketing, loan repayment, deferred compensation, litigation settlements, and working capital. · Underwriters ThinkEquity LLC

Regentis Biomaterials Ltd. is conducting an IPO to raise funds for clinical development, PMA submission, and commercialization of its GelrinC hydrogel platform for knee cartilage repair. The offering includes 1,000,000 ordinary shares at $10.00-$12.00 per share, with proceeds allocated to clinical trials, manufacturing, R&D, EU market development, and debt repayment. The company highlights Phase II trial results showing superior efficacy over microfracture, CE mark approval in Europe, and an FDA PMA trial underway. The offering is underwritten by ThinkEquity LLC, with expected listing on NYSE American.

2025-10-06 · 0001213900-25-096296

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds general corporate purposes · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of 1,000,000 ordinary shares at an estimated price range of $10.00 to $12.00 per share. The company, an emerging growth company and foreign private issuer, focuses on regenerative medicine solutions for orthopedic tissue repair, particularly GelrinC, a hydrogel-based treatment for knee cartilage injuries. The IPO follows regulatory approvals in Europe and plans to engage European partners for commercialization. The filing includes detailed risk factors, underwriting terms, and financial disclosures.

2025-09-30 · 0001213900-25-093302

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows F-1/A and registers the class of securities for exchange listing.

Regentis Biomaterials Ltd. filed Form 8-A12B to register its ordinary shares (no par value) on NYSE American, LLC. The filing incorporates by reference the share capital description from its prior F-1 registration statement (filed March 2025) and confirms the securities are not registered under Section 12(g) of the Exchange Act. No new material information is provided beyond the registration process.

2025-09-09 · 0001213900-25-086109

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Regentis Biomaterials Ltd. filed an amended registration statement (F-1/A) for its upcoming IPO, updating details on recent securities offerings, loan agreements, and use of proceeds. The filing highlights the company's focus on its GelrinC hydrogel technology for knee cartilage repair, with ongoing FDA pivotal trials and plans for EU commercialization. The company also disclosed updated indemnification policies for directors and officers, while noting the unenforceability of certain indemnifications under U.S. securities law.

2025-09-09 · 0001213900-25-085690

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows F-1/A and supplements the active offering with updated prospectus details.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds Proceeds will be used for clinical development, PMA submission, operations, R&D, EU marketing, loan repayment, deferred compensation, litigation settlement, and working capital. · Underwriters ThinkEquity LLC

Regentis Biomaterials Ltd. is conducting an IPO offering 1,000,000 ordinary shares at an expected price range of $10.00-$12.00 per share. The company develops GelrinC, an acellular hydrogel for knee cartilage repair, with CE mark approval in Europe and an ongoing FDA pivotal trial. Proceeds will fund clinical development, PMA submission, operations, R&D, EU marketing, and other purposes. The offering is underwritten by ThinkEquity LLC.

2025-07-07 · 0001213900-25-061829

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds working capital · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an IPO for 1,000,000 ordinary shares, with an expected price range of $10.00-$12.00 per share. The company develops regenerative medicine solutions, focusing on orthopedic treatments using its GelrinC hydrogel platform for knee cartilage repair. The offering includes a 45-day option for underwriters to purchase additional shares. The company is an emerging growth company and a foreign private issuer, with its shares approved for NYSE American listing under the symbol RGNT.

2025-07-07 · 0001213900-25-061821

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds for general corporate purposes · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is seeking to raise capital through an initial public offering (IPO) of 1,000,000 ordinary shares, with an expected price range of $10.00 to $12.00 per share. The company, an emerging growth company and foreign private issuer, develops regenerative medicine solutions for orthopedic applications, primarily through its Gelrin platform. Its lead product, GelrinC, is a hydrogel-based treatment for knee cartilage injuries, approved in Europe with a CE mark. The IPO aims to fund clinical trials, regulatory approvals, and commercialization efforts, with underwriters including ThinkEquity. The filing highlights risks related to regulatory approval, reliance on a single product, and clinical trial outcomes.

2025-05-19 · 0001213900-25-045479

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an IPO of 1,000,000 ordinary shares at an estimated price range of $10.00 to $12.00 per share, with an option for underwriters to purchase additional shares. The company, focused on regenerative medicine, offers GelrinC, a hydrogel-based treatment for knee cartilage injuries. The filing reflects changes from the previous F-1, including a shift in listing exchange from Nasdaq to NYSE American and updates to underwriting details.

2025-05-05 · 0001213900-25-039589

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Price $11.00 · Range $10.00 to $12.00 · 909,090 shares

Ordinary Shares · Exchange Nasdaq Capital Market · Ticker RGNT · Over-allotment 136,364 · Flags foreign_private_issuer · Underwriters ThinkEquity

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of 909,090 ordinary shares at an estimated price range of $10.00 to $12.00 per share. The company develops GelrinC, a hydrogel-based treatment for knee cartilage injuries, which has received CE marking in Europe but remains unapproved by the FDA. The IPO aims to fund clinical trials, commercialization, and general operations, with the company positioned as an emerging growth company and foreign private issuer under U.S. securities laws.

2025-03-11 · 0001213900-25-022350

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Regentis Biomaterials Ltd. is conducting a firm commitment initial public offering (IPO) of ordinary shares, aiming to list on the Nasdaq Capital Market under the symbol RGNT. The company develops regenerative medicine solutions, with its lead product candidate, GelrinC, a cell-free hydrogel for treating knee cartilage injuries. The IPO seeks to raise capital for commercialization, clinical development, and operational expansion. The offering is subject to regulatory approvals and market conditions.

2025-02-12 · 0001213900-25-012299

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Regentis Biomaterials Ltd. is conducting a firm commitment initial public offering (IPO) of ordinary shares, aiming to raise capital for its orthopedic tissue repair solutions. The company's lead product, GelrinC, is a cell-free hydrogel designed to regenerate knee cartilage and has received CE marking in Europe. The IPO price range is unspecified, and the company plans to list on the Nasdaq Capital Market under the symbol RGNT. Regentis is an emerging growth company subject to reduced reporting requirements and faces risks related to market acceptance, regulatory approvals, and clinical trial outcomes.

2025-01-27 · 0001213900-25-006676

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after DRS.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of ordinary shares, focusing on its GelrinC product for knee cartilage repair. The company aims to list on the Nasdaq Capital Market under the symbol RGNT. The IPO involves underwriters like ThinkEquity, with an estimated price range and potential proceeds for product development and commercialization. The offering is subject to regulatory approvals and market conditions.

2025-01-24 · 0001213900-25-006245

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after RW.

Regentis Biomaterials Ltd. has filed a new F-1 registration statement for an initial public offering (IPO) of ordinary shares, following a previous withdrawal request (RW) in 2024. The company, an emerging growth company and foreign private issuer, aims to list on Nasdaq under the symbol RGNT. The offering includes ordinary shares with an estimated price range, underwriting discounts, and a potential over-allotment option. The filing highlights risks related to market acceptance, regulatory approvals, and dependence on a single product candidate, GelrinC, for orthopedic tissue repair.

2024-11-21 · 0001213900-24-101093

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows F-1/A and ends the active registration process.

Regentis Biomaterials Ltd. has withdrawn its initial public offering (IPO) registration statement (Form F-1) with the SEC, citing the decision to abandon the offering. The company previously filed an amended registration statement (F-1/A) in December 2022, but now seeks to withdraw it under Rule 477(a) of the Securities Act, as no securities have been sold and the registration was never declared effective.

2024-11-21 · 0001213900-24-101083

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

2,022 shares

Ordinary Shares · Exchange Nasdaq Capital Market · Ticker RBTI · Units consisting of Ordinary Shares and Warrants · Warrants exercisable at 100% of IPO price, expiring 5 years from issuance · Use of proceeds General corporate purposes · Flags foreign_private_issuer, emerging_growth_company · Underwriters Maxim Group LLC

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units consisting of ordinary shares and warrants to purchase ordinary shares. The company, an emerging growth company, focuses on developing regenerative medicine solutions, particularly GelrinC, a hydrogel-based treatment for knee cartilage injuries. The offering aims to raise up to $15 million, with shares and warrants to be listed on the Nasdaq Capital Market. The filing includes details on underwriting, risks, and the company's financial and operational structure.

2022-12-19 · 0001213900-22-080923

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

2,022 shares

ordinary share · Exchange NASDAQ · Units consisting of one ordinary share and one warrant to purchase one ordinary share · Warrants exercisable at $ per share, expiring five years from issuance · Use of proceeds Proceeds will be used for general corporate purposes · Flags foreign_private_issuer, units, warrants · Underwriters Maxim Group LLC

Regentis Biomaterials Ltd., an Israeli regenerative medicine company, is conducting an initial public offering (IPO) to raise $15 million through the sale of units consisting of ordinary shares and warrants. The company focuses on orthopedic treatments using its Gelrin platform, a degradable hydrogel for tissue regeneration. Its lead product, GelrinC, is approved in Europe but lacks strategic partners for commercialization. The IPO is conditional on Nasdaq listing approval, and the company is an emerging growth company subject to reduced reporting requirements.

2022-12-07 · 0001213900-22-078151

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

2,022 shares

ordinary share · Exchange Nasdaq Capital Market · Ticker AND · Units consisting of one ordinary share and one warrant to purchase one ordinary share · Warrants to purchase ordinary shares at an exercise price of $ per share, exercisable immediately and expiring five years from issuance · Flags foreign_private_issuer, units · Underwriters Maxim Group LLC

Regentis Biomaterials Ltd. is conducting its initial public offering (IPO) to raise capital through the issuance of units consisting of ordinary shares and warrants. The company, incorporated in Israel, focuses on developing regenerative medicine solutions, particularly GelrinC, a hydrogel-based treatment for knee cartilage injuries. The offering includes a public offering price range, underwriting discounts, and proceeds to the company. The filing highlights risks related to regulatory approvals, product development, and market competition. The company is an emerging growth company and a foreign private issuer, subject to reduced reporting requirements.

2022-11-04 · 0001213900-22-069365

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units consisting of ordinary shares and warrants. The offering aims to raise capital for product development and commercialization, with an estimated public offering price per unit between $ and $. The company, an emerging growth company and foreign private issuer, is focused on orthopedic treatments using its Gelrin platform for cartilage regeneration. The IPO includes a provision for underwriters to purchase additional shares or warrants to cover over-allotments.

2022-09-23 · 0001213900-22-058342

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units comprising ordinary shares and warrants to purchase ordinary shares. The company, an emerging growth company and foreign private issuer, is seeking to list its ordinary shares on the Nasdaq Capital Market. The offering includes a structured pricing range, underwriting discounts, and a potential over-allotment option. The prospectus highlights risks related to regulatory approvals, market competition, and reliance on its lead product candidate, GelrinC, which is CE-marked but requires strategic partnerships for commercialization.

2022-08-22 · 0001213900-22-050139

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units consisting of ordinary shares and warrants to purchase ordinary shares. The company, an emerging growth company and foreign private issuer, focuses on developing regenerative medicine solutions, particularly GelrinC, a hydrogel for knee cartilage repair. The offering is subject to regulatory approvals, and the company plans to list its shares on Nasdaq. The filing includes underwriting details, risk factors, and legal disclosures.

2022-07-22 · 0001213900-22-040885

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Regentis Biomaterials Ltd. is conducting its initial public offering (IPO) to raise capital through the sale of units consisting of ordinary shares and warrants. The company, incorporated in Israel, focuses on regenerative medicine solutions using its Gelrin platform for orthopedic tissue repair. Its lead product, GelrinC, is a hydrogel implant for knee cartilage injuries, approved in Europe with a CE mark. The IPO aims to fund commercialization efforts, with shares and warrants listed on Nasdaq. The offering includes a 45-day option for underwriters to cover over-allotments. The company is an emerging growth company with reduced reporting requirements.

2022-03-29 · 0001213900-22-015639

REGENTIS BIOMATERIALS LTD.

Filing Timeline

5 comparable deals

Recent News